Virtus ETF Advisers LLC Has $83,000 Holdings in uniQure (NASDAQ:QURE)

Virtus ETF Advisers LLC cut its stake in uniQure (NASDAQ:QURE) by 73.1% in the fourth quarter, HoldingsChannel.com reports. The fund owned 4,721 shares of the biotechnology company’s stock after selling 12,835 shares during the period. Virtus ETF Advisers LLC’s holdings in uniQure were worth $83,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. China Universal Asset Management Co. Ltd. increased its stake in shares of uniQure by 9.6% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,062 shares of the biotechnology company’s stock valued at $195,000 after acquiring an additional 969 shares during the last quarter. Wells Fargo & Company MN increased its stake in shares of uniQure by 13.9% in the 4th quarter. Wells Fargo & Company MN now owns 12,294 shares of the biotechnology company’s stock valued at $217,000 after acquiring an additional 1,503 shares during the last quarter. Twin Tree Management LP bought a new stake in uniQure during the 4th quarter worth approximately $77,000. FNY Investment Advisers LLC bought a new stake in uniQure during the 4th quarter worth approximately $88,000. Finally, Geode Capital Management LLC increased its stake in uniQure by 1.3% during the 3rd quarter. Geode Capital Management LLC now owns 508,602 shares of the biotechnology company’s stock worth $2,509,000 after purchasing an additional 6,362 shares in the last quarter. 78.83% of the stock is owned by institutional investors.

Analyst Ratings Changes

QURE has been the subject of a number of research reports. Wells Fargo & Company lowered their target price on uniQure from $35.00 to $30.00 and set an “equal weight” rating for the company in a research note on Friday, February 28th. Chardan Capital initiated coverage on uniQure in a research note on Tuesday, April 1st. They set a “buy” rating and a $38.00 target price for the company. StockNews.com raised uniQure to a “sell” rating in a research note on Tuesday, March 11th. Royal Bank of Canada reissued an “outperform” rating and set a $24.00 target price on shares of uniQure in a research note on Tuesday, January 21st. Finally, HC Wainwright reissued a “buy” rating and set a $70.00 target price on shares of uniQure in a research note on Monday, April 21st. One research analyst has rated the stock with a sell rating, three have given a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $38.80.

uniQure Trading Down 1.5 %

NASDAQ:QURE opened at $13.97 on Tuesday. uniQure has a twelve month low of $3.73 and a twelve month high of $19.18. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92. The business has a 50 day moving average price of $11.95 and a two-hundred day moving average price of $11.68. The company has a market cap of $755.46 million, a P/E ratio of -2.82 and a beta of 0.42.

Insider Activity

In other news, CFO Christian Klemt sold 14,341 shares of the stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $10.70, for a total value of $153,448.70. Following the completion of the sale, the chief financial officer now owns 152,372 shares of the company’s stock, valued at approximately $1,630,380.40. This represents a 8.60 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Matthew C. Kapusta sold 28,341 shares of the stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $10.29, for a total value of $291,628.89. Following the completion of the sale, the chief executive officer now directly owns 651,454 shares of the company’s stock, valued at approximately $6,703,461.66. The trade was a 4.17 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 90,830 shares of company stock valued at $961,401. 4.74% of the stock is owned by insiders.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.